Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy
Morton, Gerard, Chung, Hans T., McGuffin, Merrylee, Helou, Joelle, D’Alimonte, Laura, Ravi, Ananth, Cheung, Patrick, Szumacher, Ewa, Liu, Stanley, Al-Hanaqta, Motasem, Zhang, Liying, Mamedov, AlexandrLanguage:
english
Journal:
Radiotherapy and Oncology
DOI:
10.1016/j.radonc.2016.10.019
Date:
November, 2016
File:
PDF, 825 KB
english, 2016